400 related articles for article (PubMed ID: 33200345)
1. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab.
Yoshikawa Y; Imamura M; Yamaoka K; Kosaka Y; Murakami E; Morio K; Fujino H; Nakahara T; Okamoto W; Yamauchi M; Kawaoka T; Tsuge M; Hiramatsu A; Hayes CN; Aikata H; Fujitaka K; Arihiro K; Hattori N; Chayama K
Clin J Gastroenterol; 2021 Feb; 14(1):283-287. PubMed ID: 33200345
[TBL] [Abstract][Full Text] [Related]
2. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.
Hirasawa Y; Yoshimura K; Matsui H; Kubota Y; Ishida H; Arai J; Sakaki M; Oguro N; Shida M; Taniguchi M; Hamada K; Ariizumi H; Ishiguro T; Ohkuma R; Sambe T; Horiike A; Imamura CK; Shiozawa E; Wada S; Tsurutani J; Iwamoto S; Uchida N; Kiuchi Y; Tate G; Kobayashi S; Tsunoda T
Medicine (Baltimore); 2021 Jun; 100(23):e25774. PubMed ID: 34114983
[TBL] [Abstract][Full Text] [Related]
3. Sclerosing cholangitis in a patient treated with nivolumab.
Talbot S; MacLaren V; Lafferty H
BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34049893
[TBL] [Abstract][Full Text] [Related]
4. Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up.
McClure T; Cui W; Asadi K; John T; Testro A
BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32912846
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report.
Nabeshima S; Yamasaki M; Matsumoto N; Takaki S; Nishi Y; Kawamoto K; Taniwaki M; Ohashi N; Hattori N
Cancer Treat Res Commun; 2021; 26():100270. PubMed ID: 33338849
[TBL] [Abstract][Full Text] [Related]
6. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review.
Onoyama T; Takeda Y; Yamashita T; Hamamoto W; Sakamoto Y; Koda H; Kawata S; Matsumoto K; Isomoto H
World J Gastroenterol; 2020 Jan; 26(3):353-365. PubMed ID: 31988594
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report.
Sato K; Hayashi M; Abe K; Fujita M; Takahashi A; Ohira H
Clin J Gastroenterol; 2020 Dec; 13(6):1310-1314. PubMed ID: 32643124
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of laparoscopy and intraductal ultrasonography in a patient with isolated immunoglobulin G4-related sclerosing cholangitis.
Ohno Y; Kumagi T; Imamura Y; Kuroda T; Koizumi M; Watanabe T; Yoshida O; Tokumoto Y; Takeshita E; Abe M; Harada K; Hiasa Y
Clin J Gastroenterol; 2018 Feb; 11(1):62-68. PubMed ID: 29094322
[TBL] [Abstract][Full Text] [Related]
9. Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case.
Kataoka S; Moriguchi M; Okishio S; Takahashi A; Okuda K; Seko Y; Umemura A; Yamaguchi K; Miyagawa-Hayashino A; Itoh Y
Clin J Gastroenterol; 2022 Apr; 15(2):467-474. PubMed ID: 35201598
[TBL] [Abstract][Full Text] [Related]
10. Immune-related adverse event-associated sclerosing cholangitis due to immune checkpoint inhibitors: imaging findings and treatments.
Okamoto K; Hijioka S; Nagashio Y; Okada M; Ohba A; Maruki Y; Kondo S; Morizane C; Ueno H; Okusaka T
Jpn J Clin Oncol; 2024 May; ():. PubMed ID: 38715325
[TBL] [Abstract][Full Text] [Related]
11. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.
Kawakami H; Tanizaki J; Tanaka K; Haratani K; Hayashi H; Takeda M; Kamata K; Takenaka M; Kimura M; Chikugo T; Sato T; Kudo M; Ito A; Nakagawa K
Invest New Drugs; 2017 Aug; 35(4):529-536. PubMed ID: 28317087
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune sclerosing cholangitis: Evidence and open questions.
Terziroli Beretta-Piccoli B; Vergani D; Mieli-Vergani G
J Autoimmun; 2018 Dec; 95():15-25. PubMed ID: 30366655
[TBL] [Abstract][Full Text] [Related]
13. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis.
Sterling RK; Salvatori JJ; Luketic VA; Sanyal AJ; Fulcher AS; Stravitz RT; Contos MJ; Mills AS; Shiffman ML
Aliment Pharmacol Ther; 2004 Nov; 20(9):943-9. PubMed ID: 15521841
[TBL] [Abstract][Full Text] [Related]
14. Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report.
Tanaka T; Sakai A; Tsujimae M; Yamada Y; Kobayashi T; Masuda A; Kodama Y
World J Gastroenterol; 2022 Jul; 28(28):3732-3738. PubMed ID: 36161046
[TBL] [Abstract][Full Text] [Related]
15. Radiologic manifestations of sclerosing cholangitis with emphasis on MR cholangiopancreatography.
Vitellas KM; Keogan MT; Freed KS; Enns RA; Spritzer CE; Baillie JM; Nelson RC
Radiographics; 2000; 20(4):959-75; quiz 1108-9, 1112. PubMed ID: 10903686
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic usefulness of precise examinations with intraductal ultrasonography, peroral cholangioscopy and laparoscopy of immunoglobulin G4-related sclerosing cholangitis.
Horiguchi S; Ikeda F; Shiraha H; Yamamoto N; Sakakihara I; Noma Y; Tsutsumi K; Kato H; Hagihara H; Yasunaka T; Nakamura S; Kobashi H; Kawamoto H; Yamamoto K
Dig Endosc; 2012 Sep; 24(5):370-3. PubMed ID: 22925292
[TBL] [Abstract][Full Text] [Related]
17. Intrahepatic segmental primary sclerosing cholangitis: report of a case.
Matsumoto T; Ajiki T; Matsumoto I; Tominaga M; Hori H; Mita Y; Fujita T; Fujino Y; Suzuki Y; Ku Y; Kuroda Y
Surg Today; 2006; 36(7):638-41. PubMed ID: 16794801
[TBL] [Abstract][Full Text] [Related]
18. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report.
Kashima J; Okuma Y; Shimizuguchi R; Chiba K
Cancer Immunol Immunother; 2018 Jan; 67(1):61-65. PubMed ID: 28913619
[TBL] [Abstract][Full Text] [Related]
19. Inter-reader agreement of interpretation of radiological course of bile duct changes between serial follow-up magnetic resonance imaging/3D magnetic resonance cholangiopancreatography of patients with primary sclerosing cholangitis.
Grigoriadis A; Morsbach F; Voulgarakis N; Said K; Bergquist A; Kartalis N
Scand J Gastroenterol; 2020 Feb; 55(2):228-235. PubMed ID: 32024405
[No Abstract] [Full Text] [Related]
20. Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab.
Noda-Narita S; Mizuno S; Noguchi S; Watanabe K; Nakai Y; Koike K; Kage H; Nagase T
Eur J Cancer; 2019 Jan; 107():93-96. PubMed ID: 30554074
[No Abstract] [Full Text] [Related]
[Next] [New Search]
